Candida albicans
- Generic Name
- Candida albicans
- Brand Names
- Candin
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 4D7G21HDBC
- Background
Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing.
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT05522517
- Locations
- π§πͺ
Clinical Pharmacology Unit, Antwerpen, Belgium
Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens
Phase 1
Terminated
- Conditions
- Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05216510
- Locations
- πΊπΈ
Clinical Site, Berlin, New Jersey, United States
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT04611971
- Locations
- π§πͺ
Clinical Pharmacology Unit, Merksem, Belgium
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT04589026
- Locations
- π§πͺ
Clinical Pharmacology Unit, Merksem, Belgium
A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants
Early Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Other: Skin BiopsyBiological: LPSOther: Saline Control
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT03953196
- Locations
- π§πͺ
Clinical Pharmacology Unit, Merksem, Belgium
Immunologic Profile of Chronically Photodamaged Skin
Phase 1
Completed
- Conditions
- Normal SkinPhotoaged Skin
- Interventions
- Procedure: Tape Stripping
- First Posted Date
- 2016-09-05
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 40
- Registration Number
- NCT02889159
- Locations
- πΊπΈ
University of Michigan Department of Dermatology, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath